Credit Rating

Date: July 03, 2026 BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Intimation of Revision in Credit Rating Dear Sir / Madam, Pursuant to Regulation 30 read with Clause 3 of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular dated January 30, 2026, it is hereby informed that, ICRA Limited ("ICRA") has revised the credit ratings assigned to the bank facilities of the Company based on its latest rating assessment. The details of the revised credit ratings are as follows: Credit Instrument Rated Rating Rating Amount Agency (Rs. Crores) ICRA Long Term/Short Term 175 [ICRA]AA (Stable) (Upgraded from [ICRA]AA- (Positive); Limited –Fund Based – Outlook revised from Positive to Stable) /[ICRA]A1+ Working Capital reaffirmed Long Term – Fund 67.50 [ICRA]AA (Stable) (Upgraded from [ICRA]AA- (Positive); Based – Term Loan Outlook revised from Positive’ to Stable); Assigned for enhanced limit Short Term – Non- 10 [ICRA]A1+; assigned for enhanced limit Fund based-others Long Term/ Short 23 [ICRA]AA (Stable); (Upgraded from [ICRA]AA- (Positive); Term – Unallocated Outlook revised from Positive to Stable) / [ICRA]A1+ reaffirmed; Assigned for enhanced limit The rating letter dated July 02, 206 issued by the ICRA is enclosed herewith. The above information is also available on the website of the Company at https://anthembio.com/investors/. You are requested to take the above information on record. Thanking you, Yours truly, For Anthem Biosciences Limited (Formerly known as Anthem Biosciences Private Limited) Divya Prasad Company Secretary & Compliance Officer Membership No: A41438 ICRA Limited ICRA/Anthem Biosciences Limited/02072026/01 Date: July 02, 2026 Mr. Gawir Baig Chief Financial Officer Anthem Biosciences Limited 49, F1& F2, Canara Bank Road, Bommasandra Industrial Area- Phase I Bommasandra, Bangalore – 560 099 Dear Sir, Re: ICRA’s Credit Rating for below mentioned Instruments of Anthem Biosciences Limited As per the Rating Agreement/Statement of Work executed with ICRA Limited, ICRA’s Rating Committee has taken the following rating actions for the mentioned instruments of your company. Instrument Rated Amount Rating Action1 (Rs. crore) [ICRA]AA (Stable); upgraded from [ICRA]AA- (Positive) and Long Term/Short Term – Fund Based – 175.0 outlook revised to ‘Stable’ from ‘Positive’/[ICRA]A1+; Working Capital reaffirmed [ICRA]AA (Stable); upgraded from [ICRA]AA- (Positive) and Long Term – Fund Based – Term Loan 67.50 outlook revised to ‘Stable’ from ‘Positive’; Assigned for enhanced limit Short Term – Non-Fund based-others 10.0 [ICRA]A1+; assigned for enhanced limit [ICRA]AA (Stable); upgraded from [ICRA]AA-(Positive)/ Long Term/ Short Term – Unallocated 23.00 [ICRA] A1+; reaffirmed and outlook revised to ‘Stable’ from ‘Positive’; Assigned for enhanced limit Total 275.50 The aforesaid rating(s) will become due for surveillance within one year from the date of rating communication letter. However, ICRA reserves the right to review and/or, revise the above rating(s) at any time based on new information becoming available, or the required information not being available, or other circumstances that ICRA believes could have an impact on the rating(s). Therefore, request the lenders and investors to visit ICRA website at www.icra.in for latest rating(s) of the company. The rating(s) are specific to the terms and conditions of the instruments as indicated to us by you, and any change in the terms or size of the same would require a review of the rating(s) by us. In case there is any change in the terms and conditions or the size of the rated instrument, the same must be brought to our notice before the instrument is used by you. In the event such changes occur after the rating(s) have been assigned by us and their use has been confirmed by you, the rating(s) would be subject to our review, following which there could be a change in the rating(s) previously assigned. Notwithstanding the foregoing, any change in the over- all limit of the instrument from that specified in this letter, would constitute an enhancement that would not be covered by or under the said Rating Agreement. The rating(s) assigned must be understood solely as an opinion and should not be treated, or cause to be treated, as recommendation to buy, sell, or hold the rated instrument availed/issued by your company. You are also requested to forthwith inform us about any default or delay in repayment of interest or principal amount of the instrument rated, as above, or any other debt instruments/ borrowing and keep us informed of any other developments which may have a direct or indirect impact on the debt servicing capability of the company including any proposal for re-schedulement or 1 Complete definitions of the ratings assigned are available at www.icra.in. BuilSdeinngs Nitoiv. i8ty, 2 Lnad bFelolo :r ,R Teoswterirc Ate d Tel.: +91.124 .4545300 Website: www.icra.in DLF Cyber City, Phase II CIN: L749999DL1991PLC042749 Email: info@icraindia.com Gurugram – 122002, Haryana Helpdesk: +91 9354738909 Registered Office: B-710, Statesman House, 148, Barakhamba Road, New Delhi 110001. Tel.: +91.11.23357940-41 RATING ● RESEARCH ● INFORMATION postponement of the repayment programmes of the dues/ debts of the company with any lender(s) / investor(s), or occurrence of any significant development that could impact the ability of the company to raise funds such as restriction imposed by any authority from raising funds through issuance of debt securities through electronic bidding system. Further, you are requested to inform us immediately as and when the borrowing limit for the instrument rated, as above, or as prescribed by the regulatory authority(ies) is exceeded. We look forward to your communication and assure you of our best services. Ankit Jain Vice President ankit.jain@icraindia.com Sensitivity Label : Restricted Annexure Details of Bank Limits Rated by ICRA (Rated on Long Term/Short Amount (Rs. crore) Rating Rating Assigned On term scale) Fund Based – Working Capital HDFC Bank-Working Capital 25.00 [ICRA]AA (Stable); upgraded from [ICRA]AA- (Positive) and Citi Bank- Working Capital 150.00 June 26,2026 outlook revised to ‘Stable’ from Federal Bank- Working Capital 0.00 ‘Positive’/[ICRA]A1+; reaffirmed Total 175.00 Details of Bank Limits Rated by Amount (Rs. crore) Rating Rating Assigned On ICRA (Rated on Long-Term Scale) Fund Based-Term Loan [ICRA]AA (Stable); upgraded from [ICRA]AA- (Positive) and Citi Bank-Term Loan 67.50 outlook revised to ‘Stable’ from June 26,2026 ‘Positive’; Assigned for enhanced limit Total 67.50 Details of Bank Limits Rated by Amount (Rs. crore) Rating Rating Assigned On ICRA (Rated on Short term scale) Non-Fund Based-Others [ICRA]A1+; assigned for Non- Fund Based- Short term 10.00 June 26,2026 enhanced limit Total 10.00 Details of Bank Limits Rated by ICRA (Rated on Long term /Short Amount (Rs. crore) Rating Rating Assigned On term scale) [ICRA]AA (Stable); upgraded from [ICRA]AA-(Positive)/ [ICRA] A1+; reaffirmed and outlook Unallocated Limits 23.00 June 26,2026 revised to ‘Stable’ from ‘Positive’; Assigned for enhanced limit Total 23.00 Sensitivity Label : Restricted